Literature DB >> 3971657

Cigarette smoking and theophylline metabolism: effects of cimetidine.

B J Cusack, G W Dawson, G D Mercer, R E Vestal.   

Abstract

The inhibition of theophylline metabolism by cimetidine was investigated in young male cigarette smokers (greater than 20 cigarettes/day) and nonsmokers by stable isotope methodology. Subjects received oral theophylline (510 mg/day) for 14 days and cimetidine (1200 mg/day) over days 1 to 7 or 8 to 14. On days 7 and 14, a tracer dose (10 mg) of stable isotope-labeled theophylline was injected intravenously with the oral dose of theophylline. Serial plasma samples were then obtained for 24 hours and both molecular forms of theophylline were assayed by mass spectrometry after purification by HPLC. Theophylline bioavailability, volume of distribution, and protein binding were of the same order in both groups and were not affected by cimetidine. Although the basal theophylline elimination rate constant was 46% greater and clearance was 54% greater in smokers than in nonsmokers, the proportionate changes in steady-state plasma concentrations, t1/2, and clearance due to cimetidine were much the same in both groups. Plasma thiocyanate concentrations were higher in smokers than in nonsmokers and were related to theophylline clearance. Our findings indicate that cimetidine inhibits theophylline metabolism to a similar extent in both smokers and nonsmokers. Determination of plasma thiocyanate levels may be valuable in the prediction of theophylline clearance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3971657     DOI: 10.1038/clpt.1985.48

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics.

Authors:  L G Miller
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

4.  Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers.

Authors:  C M Loi; B M Parker; B J Cusack; R Vestal
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

Review 5.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

6.  The effect of tocainide on theophylline metabolism.

Authors:  C M Loi; X Wei; B M Parker; M R Korrapati; R E Vestal
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 7.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

8.  Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes.

Authors:  R E Vestal; K E Thummel; G D Mercer; J R Koup
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease.

Authors:  John A Marwick; Kian Fan Chung
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-09-07

Review 10.  Differential pharmacokinetics of theophylline in elderly patients.

Authors:  Akihiro Ohnishi; Motokazu Kato; Jun Kojima; Hideki Ushiama; Maki Yoneko; Hiroyuki Kawai
Journal:  Drugs Aging       Date:  2003       Impact factor: 4.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.